Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of SHR-1701 in Advanced Solid Tumors
NCT03774979Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Jan 2019
- Primary completion
- Mar 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of retlirafusp alfa in solid tumor, sponsored by Hengrui. Primary endpoints: Safety and tolerability of SHR-1701 in advanced malignancies up to 4 weeks and Objective Response Rate up to 6 weeks. Status: unknown.
02
Drugs
retlirafusp alfa
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03774979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03774979.